Summary: Cigna Healthcare modified its coverage policy for genetic testing for reproductive carrier screening and prenatal diagnosis (Policy 0514), effective April 11, 2026. Here's what billing teams need to do.
Cigna Healthcare updated Policy 0514, which governs coverage for genetic testing used in reproductive carrier screening and prenatal diagnosis. This is one of the more financially significant policy areas in women's health billing — genetic testing claims run high, prior authorization requirements are strict, and denials in this category are common. The policy does not list specific CPT or HCPCS codes in the data available at publication, so billing teams should pull the full policy document directly from Cigna to confirm code-level applicability before the April 11, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis |
| Policy Code | 0514 |
| Change Type | Modified |
| Effective Date | April 11, 2026 |
| Impact Level | High |
| Specialties Affected | OB/GYN, Maternal-Fetal Medicine, Reproductive Endocrinology, Clinical Genetics, Laboratory/Pathology |
| Key Action | Review updated medical necessity criteria against your current order and documentation workflows before April 11, 2026 |
Cigna Genetic Testing for Reproductive Carrier Screening Coverage Criteria and Medical Necessity Requirements 2026
The Cigna genetic testing coverage policy under Policy 0514 covers a clinically meaningful and financially significant territory. Reproductive carrier screening and prenatal genetic testing are among the highest-volume genetic testing categories in outpatient women's health billing. Getting the medical necessity criteria wrong costs real money.
Cigna's coverage position on reproductive genetic testing has historically followed a tiered model. Coverage depends on the patient's clinical situation — whether they're a candidate for carrier screening before or during pregnancy, whether there's a personal or family history indicating elevated risk, and what specific test or panel is being ordered. Medical necessity documentation needs to match the indication exactly.
For carrier screening, Cigna has generally covered testing for conditions where the patient or partner belongs to a population with elevated carrier frequency — conditions like cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and hemoglobinopathies. Expanded carrier screening panels are an area where Cigna has drawn sharper lines. Coverage for broad expanded panels without clear medical necessity justification has been a consistent source of claim denial.
For prenatal diagnosis, coverage has centered on situations with documented elevated risk — advanced maternal age, abnormal screening results (including cell-free fetal DNA/cfDNA), or known familial genetic variants. Procedures like chorionic villus sampling and amniocentesis for genetic analysis have had stronger coverage support than some of the newer sequencing-based approaches, which Cigna has been slower to cover broadly.
Prior authorization requirements apply to many tests in this category. If your practice orders prenatal genetic panels without running prior auth first, you're building claims that will hit a wall. Confirm prior authorization requirements for every code you bill under this policy before April 11, 2026.
The real issue with Policy 0514 is that Cigna's medical necessity criteria in this space have been getting more specific — not more permissive. If your documentation doesn't tie the ordered test to an explicit indication Cigna recognizes, expect denial. Vague language like "patient requested" or "family history of genetic conditions" without specifics is not going to hold up.
Cigna Genetic Testing for Reproductive Carrier Screening Exclusions and Non-Covered Indications
Cigna has consistently excluded or limited several categories within reproductive genetic testing. Understanding where the coverage policy draws the line is as important as knowing what's covered.
Whole exome and whole genome sequencing for routine prenatal or carrier screening purposes has generally not met Cigna's medical necessity threshold. These tests may be covered in narrower circumstances — such as when a fetal anomaly is detected and standard testing is inconclusive — but they are not covered as first-line tools.
Expanded carrier screening panels ordered without documented clinical indication have been a persistent exclusion. Ordering a 200+ condition panel because a patient wants to "know everything" doesn't satisfy Cigna's medical necessity criteria. The indication has to be specific and documented.
Preimplantation genetic testing (PGT) — including PGT-A (aneuploidy screening) and PGT-M (monogenic disorders) — falls into a separate coverage territory that Cigna has treated inconsistently across plan types. Some commercial plans exclude it entirely. If you're billing PGT codes, don't assume Policy 0514 governs coverage — that may fall under a separate fertility or IVF policy.
Direct-to-consumer or patient-initiated testing submitted for reimbursement without a physician order tied to a clinical indication will not meet Cigna's coverage criteria.
If any of these scenarios describe a meaningful portion of your test ordering patterns, talk to your compliance officer before April 11, 2026.
Coverage Indications at a Glance
Because the policy data available at publication does not include indication-level detail from the updated document itself, the table below reflects Cigna's known coverage framework for Policy 0514. Pull the full updated policy from Cigna's provider portal to confirm any changes to these positions.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Carrier screening for autosomal recessive conditions (CF, SMA, hemoglobinopathies) in appropriate populations | Covered | Not specified in available data | Medical necessity documentation required; specific conditions vary |
| Expanded carrier screening panels with documented clinical indication | Covered (limited) | Not specified in available data | Prior authorization typically required; indication must be explicit |
| Expanded carrier screening panels without specific clinical indication | Not Covered | Not specified in available data | "Patient request" alone does not satisfy medical necessity |
| Prenatal diagnosis via amniocentesis or CVS for elevated-risk pregnancies | Covered | Not specified in available data | Advanced maternal age, abnormal screen, or known familial variant required |
| Cell-free fetal DNA (cfDNA) screening for high-risk pregnancies | Covered | Not specified in available data | Criteria apply; not covered as routine low-risk screening in all plans |
| Whole exome/genome sequencing for routine prenatal screening | Not Covered / Experimental | Not specified in available data | May be covered in narrow circumstances with documented anomaly |
| Preimplantation genetic testing (PGT-A, PGT-M) | Varies by plan | Not specified in available data | May fall under separate fertility policy — verify separately |
Cigna Genetic Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full updated Policy 0514 document before April 11, 2026. The data available at publication does not include code-level changes. Get the complete document from Cigna's provider portal or through your Cigna provider relations contact. You need to know exactly which CPT and HCPCS codes are affected. |
| 2 | Audit your prior authorization workflows for every genetic test you order against Cigna. Prior authorization requirements in this category are real and enforced. If your ordering physicians aren't consistently checking PA requirements before ordering reproductive genetic tests, fix that process now — not after you've built a stack of denied claims. |
| 3 | Review your medical necessity documentation templates. Generic documentation won't survive Cigna's scrutiny under Policy 0514. Each order needs to tie to a specific, recognized indication. Work with your medical director or ordering physicians to tighten up order documentation before the effective date. |
| 4 | Separate your Cigna reproductive genetic testing claims by indication type. Carrier screening, prenatal diagnosis, and preimplantation testing are not the same category under this policy. If your billing team is treating them uniformly, you're setting up for inconsistent reimbursement and claim denial patterns that are hard to trace. |
| 5 | Confirm whether cfDNA screening claims are affected. Cell-free fetal DNA screening codes have been a moving target across major payers. Cigna's position on cfDNA under Policy 0514 may have shifted in this update. Verify coverage criteria for cfDNA specifically, because it sits at the intersection of screening and diagnostic testing — a line Cigna watches closely. |
| 6 | Check plan-level exclusions before assuming Policy 0514 controls. Cigna sells a wide range of commercial products. Some self-funded plans have exclusions that override the standard coverage policy. Before April 11, 2026, confirm that the plans you see most often in your payer mix are actually subject to Policy 0514 as written. |
| 7 | If your practice bills expanded carrier screening panels at high volume, get your compliance officer involved. This is a category where Cigna's medical necessity criteria have been tightening. If a significant share of your genetic testing billing is in expanded panels without strong individual-case documentation, your denial rate is a risk. Have someone review your current patterns against the updated policy before you hit the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Reproductive Carrier Screening and Prenatal Diagnosis Under Policy 0514
The policy data available for this update does not include a specific code list. Cigna's Policy 0514 does not enumerate codes in the data provided at publication.
This is not unusual for Cigna's genetic testing policies — code lists in this category are long, frequently updated, and sometimes maintained in a separate reference document attached to the policy. What that means for your billing team is that you cannot rely on a summary source for code-level applicability. You need the full document.
Action: Access the complete Policy 0514 document directly at Cigna's provider portal or through the source link associated with this update. Look specifically for:
- The covered CPT codes for carrier screening panels (these typically include codes in the 81200–81400 range and the 81412–81443 range for molecular pathology)
- Any codes newly added or removed from covered status in this modification
- Codes that now require prior authorization where they previously did not
- Any codes reclassified as experimental or investigational
Do not assume the code list from a prior version of Policy 0514 still applies. This is a modification — something changed. Until you see the updated code table, you don't know what.
If your laboratory or pathology billing team is coding reproductive genetic tests, loop them in directly. Molecular pathology coding in this space is complex, and the right code selection depends on the specific test methodology and condition being screened — not just the clinical category.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.